文献速递认知障碍与痴呆帕金森病与运动障碍神经肌肉病

神经退行性疾病试验中未批准疾病修饰治疗的风险与获益

Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease.
PubMed 文献 · Neurology · 2019-12-02

该系统综述与荟萃分析纳入2005年1月至2018年5月间113项随机安慰剂对照试验(n=39,875),评估阿尔茨海默病、帕金森病、亨廷顿病或肌萎缩侧索硬化(ALS)中未获FDA批准的推测疾病修饰干预的疗效与安全性。结果显示,与安慰剂相比,主动治疗在四个适应症均无显著疗效优势,且阿尔茨海默病患者主动治疗组严重不良事件和因不良事件退出的风险更高。结论提示,参与试验时分配至安慰剂总体上未对神经退行性疾病患者造成伤害。

要点

  • 未批准疾病修饰治疗在阿尔茨海默病、帕金森病、ALS和亨廷顿病中均未显示显著疗效优势。
  • 阿尔茨海默病患者接受主动治疗时严重不良事件风险(RR 1.15)和因不良事件退出风险(RR 1.44)升高。
  • 神经退行性疾病患者参与试验时分配至安慰剂总体上未受到伤害。

核心结论

  • 在 examined 的四个适应症中,分配至主动治疗均无获益,且对阿尔茨海默病患者可能略有不利。
  • 总体而言,神经退行性疾病患者参与试验时分配至安慰剂并未受到伤害。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Embase和ClinicalTrials.gov,纳入2005年1月至2018年5月间测试未获FDA批准的推测疾病修饰干预的随机安慰剂对照试验。
  • 共纳入113项试验,39,875例患者,试验特征双人提取,研究注册于PROSPERO(CRD42018103798)。

主要发现

  • 阿尔茨海默病:主动治疗与安慰剂相比疗效无显著优势(SMD -0.03,95% CI -0.07至0.01)。
  • 帕金森病:SMD -0.09(95% CI -0.32至0.15);ALS:SMD 0.02(95% CI -0.25至0.30);亨廷顿病:SMD 0.02(95% CI -0.27至0.31),均无显著疗效优势。
  • 阿尔茨海默病患者主动治疗组严重不良事件风险比1.15(95% CI 1.04-1.27),因不良事件退出风险比1.44(95% CI 1.21-1.70)。

关键数值与推荐

  • 共同主要终点为疗效(标准化均数差)和安全性(严重不良事件及因不良事件退出的风险比),采用随机效应荟萃分析。

临床怎么用

  • 临床医生在考虑让神经退行性疾病患者参与未批准疾病修饰治疗试验时,应告知其缺乏疗效证据且阿尔茨海默病患者可能存在安全性风险。
  • 安慰剂对照试验对神经退行性疾病患者总体风险可控,可支持试验参与。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether patients randomized to unapproved, disease-modifying interventions in neurodegenerative disease trials have better outcomes than patients randomized to placebo by performing a systematic review and meta-analysis of risk and benefit experienced by patients in randomized placebo-controlled trials testing investigational treatments for Alzheimer disease, Parkinson disease, Huntington disease, or amyotrophic lateral sclerosis (ALS). METHODS: We searched MEDLINE, Embase, and ClinicalTrials.gov for results of randomized trials testing non-Food and Drug Administration-approved, putatively disease-modifying interventions from January 2005 to May 2018. Trial characteristics were double-extracted. Coprimary endpoints were the treatment advantage over placebo on efficacy (standardized mean difference in outcomes) and safety (risk ratios of serious adverse events and withdrawals due to adverse events), calculated with random effects meta-analyses. The study was registered on PROSPERO (CRD42018103798). RESULTS: We included 113 trials (n = 39,875 patients). There was no significant efficacy advantage associated with assignment to putatively disease-modifying interventions compared to placebo for Alzheimer disease (standardized mean difference [SMD] -0.03, 95% confidence interval [CI] -0.07 to 0.01), Parkinson disease (SMD -0.09, 95% CI -0.32 to 0.15), ALS (SMD 0.02, 95% CI -0.25 to 0.30), or Huntington disease (0.02, 95% CI -0.27 to 0.31). Patients with Alzheimer disease assigned to active treatment were at higher risk of experiencing serious adverse events (risk ratio [RR] 1.15, 95% CI 1.04-1.27) and withdrawals due to adverse events (RR 1.44, 95% CI 1.21-1.70). CONCLUSIONS: Assignment to active treatment was not beneficial for any of the indications examined and may have been slightly disadvantageous for patients with Alzheimer disease. Our findings suggest that patients with neurodegenerative diseases are not, on the whole, harmed by assignment to placebo when participating in trials.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Feustel AC, MacPherson A, Fergusson DA, et al. Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. Neurology. 2019. PMID: 31792092. doi:10.1212/WNL.0000000000008699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。